Healius Limited (FRA:PGZ)

Market Cap	160.45M -49.5%
Revenue (ttm)	778.30M +6.0%
Net Income	-95.90M
EPS	-0.13
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	0.24 (117.51%)
Ex-Dividend Date	May 9, 2025

Volume	n/a
Open	0.2000
Previous Close	0.2000
Day's Range	0.2000 - 0.2000
52-Week Range	0.1700 - 0.6150
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 19, 2026

About Healius

Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories and patient collection centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius ...

• Industry: Offices and Clinics of Doctors of Medicine
• Founded: 1994
• Employees: 5,962
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PGZ

Financial Performance

In fiscal year 2025, Healius's revenue was 1.34 billion, an increase of 5.69% compared to the previous year's 1.27 billion. Losses were -151.20 million, -76.59% less than in 2024.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error